Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Respiratory System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Respiratory System Neoplasm

Cancer Family

Respiratory System Neoplasm

CI-CAN-00000049Explore in graph →

Non-malignant2,727 active trials51 approved drugs619 evidence items

NCIt: C3355
MeSH: D012142

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11611
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (473)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 473 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
· Ann Oncol · 2019 · PMID 30624546 · validated civic_curation pubmed
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
· Lancet Oncol · 2012 · PMID 22452895 · validated civic_curation pubmed
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
· Nat Genet · 2014 · PMID 24658004 · validated civic_curation pubmed
The MKK7 p.Glu116Lys Rare Variant Serves as a Predictor for Lung Cancer Risk and Prognosis in Chinese.
· PLoS Genet · 2016 · PMID 27028764 · validated civic_curation pubmed
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
· Lancet Oncol · 2010 · PMID 20022809 · validated civic_curation pubmed
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
· N Engl J Med · 2009 · PMID 19692680 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411 · validated

Showing 126–150 of 473 publications

← Previous
1
…
5
6
7
…
19
Next →

civic_curation

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

· Ann Oncol · 2016 · PMID 26768165 · validated civic_curation pubmed

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

· N Engl J Med · 2022 · PMID 34534430 · validated civic_curation pubmed

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.

· Clin Cancer Res · 2021 · PMID 33355200 · validated civic_curation pubmed

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.

· J Clin Invest · 2014 · PMID 24569458 · validated civic_curation pubmed

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

· Sci Transl Med · 2011 · PMID 21430269 · validated civic_curation pubmed

Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.

· Oncology · 2014 · PMID 24457318 · validated civic_curation pubmed

The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.

· Onco Targets Ther · 2014 · PMID 24623981 · validated civic_curation pubmed

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.

· Onco Targets Ther · 2014 · PMID 24729716 · validated civic_curation pubmed

Alterations of the Notch pathway in lung cancer.

· Proc Natl Acad Sci U S A · 2009 · PMID 20007775 · validated civic_curation pubmed

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

· Clin Cancer Res · 2006 · PMID 16818686 · validated civic_curation pubmed

Rociletinib in EGFR-mutated non-small-cell lung cancer.

· N Engl J Med · 2015 · PMID 25923550 · validated civic_curation pubmed

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

· Lung Cancer · 2009 · PMID 19157633 · validated civic_curation pubmed

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

· J Thorac Oncol · 2012 · PMID 22551904 · validated civic_curation pubmed

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

· J Clin Oncol · 2013 · PMID 23182986 · validated civic_curation pubmed

FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.

· Lung Cancer · 2015 · PMID 25433983 · validated civic_curation pubmed

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

· Lancet Oncol · 2012 · PMID 22056021 · validated civic_curation pubmed

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.

· Onco Targets Ther · 2015 · PMID 26664143 · validated civic_curation pubmed

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

· PLoS One · 2015 · PMID 26086854 · validated civic_curation pubmed